This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
Third instalment of our NephJC summary tweetorials - catch it at the link to learn more about the trade-offs in timing when best to start dialysis in progressive CKD.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) February 16, 2022
✳️ 10 tweets to catch-up on the most recent #NephJC ✳️
This week - when is the ideal time to start dialysis in progressive chronic kidney disease?
Later starts lower the burden on patients & use of healthcare resources, but what’s the trade-off? pic.twitter.com/CG2YavjzEQ
Created in a time crunch, the visual abstract for this week’s study from Elena Cervantes:
